The Weekly Roundup: September 19-23

ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.

POLL: Will You Be Attending the American Society for Dermatologic Surgery 2022 Conference?

Click here to answer this week's poll.

Innovation Leads to “Windfall” in Dermatology

Continued research and development are resulting in exciting new treatment options for major dermatological conditions.

The Mainstream Patient: September 19

This week's edition of the Mainstream Patient features stories about skin cycling, skin care routines from dermatologists, upcoming nail trends, body care, and more.

Telemedicine Still Popular with Patients, but There are Concerns

Patients prefer virtual appointments for common ailments, but question the quality of care.

Role of Precision Medicine in the Management of Melanoma

Precision medicine may help improve the diagnosis and management of melanoma.

EMA Accepts Application for Extended Indication of NexoBrid for Severe Pediatric Burns

MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.

JAMA Publishes Roflumilast Cream Phase 3 Trial Results for Plaque Psoriasis

Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.

Pathogenesis of PsA and PsO

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss updates in the pathogenesis of PsA and PsO.

Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden

A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.

Patient Presentation of PsA and PsO

Drs Mark G. Lebwohl and Joseph F. Merola discuss how patient presentation differs in patients with PsO and PsA.

CHMP Recommends Use of Adtralza (tralokinumab) to Treat Adolescents with Moderate-to-Severe AD

The CHMP's recommendations are based on data from a phase 3 ECZTRA 6 trial in adolescents with moderate-to-severe AD cases.

Peptides and Skin Care

Zoe Diana Draelos, MD, answers questions about the function of peptides in skin care.

Pointers With Dr Portela: Laser Tattoo Removal

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews a video of laser tattoo removal.

Select Skin Diseases are Higher in Patients with Inflammatory Bowel Disease

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

New Guidebook Offers Basics for Health Care Systems to Address Climate Change

Federal AHRQ offers starting point for reducing greenhouse gas emissions.

The Value of Roflumilast Cream for Plaque Psoriasis

Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.